Soft Tissue Tumors

Soft tissue tumors in brief

Malignant soft tissue tumors (soft tissue sarcomas) are a group of rare cancers. They include more than 100 different tumor types that can affect the soft and connective tissue. In Germany, about 3 in 100,000 people develop one each year, which is around 2,500 people. The likelihood of developing a soft tissue tumor rises up to the age of 70; the most common age at diagnosis is between 70 and 75. Men and women are affected equally often up to the age of 70; after that, men are affected twice as often. Because these are many different diseases, no general statement about the prognosis can be made – many soft tissue tumors can be cured if they are removed completely.

Soft tissue tumors at a glance

Frequency
Rare: in Germany, about 3 in 100,000 people develop one each year, around 2,500 people
Diversity
More than 100 different tumor types of the soft and connective tissue
Typical age
Most common between 70 and 75 years
Most important treatment
Complete surgical removal of the tumor with a margin of healthy tissue

What exactly are soft tissue tumors?

The human body is made up of different, specialized groups of cells (tissues). For example, there are muscle cells, which form muscle tissue, and fat cells, which make up fat tissue. Soft tissue tumors are a group of tumors that arise from the soft and connective tissue. This includes, for example, connective tissue, fat tissue, muscle tissue, blood vessels, and nerve sheaths. During embryonic development, these tissues all arise from the same tissue of origin, the mesenchyme. Malignant soft tissue tumors are called sarcomas and are named after the tissue they arise from; two common forms are liposarcoma (from fat tissue) and leiomyosarcoma (from smooth muscle). Tumors of the bone and cartilage are covered on a separate page (see bone cancer).

Why do I have a soft tissue tumor?

Various hereditary, infectious, and external factors are known to be risk factors for soft tissue tumors. Certain risk factors increase the risk of certain soft tissue tumors. These include:

Genetic:

  • Li-Fraumeni syndrome: increased risk of rhabdomyosarcomas, fibrosarcomas, and undifferentiated pleomorphic sarcomas
  • Hereditary retinoblastoma (an eye tumor in childhood): increased risk of leiomyosarcomas
  • Familial adenomatous polyposis (FAP): increased risk of desmoid fibromatosis
  • Neurofibromatosis type 1: increased risk of malignant tumors of the nerve sheaths and
  • Carney-Stratakis syndrome (increased risk of gastrointestinal stromal tumors, GIST)

Infectious:

  • Infection with human herpesvirus 8 (HHV-8) increases the risk of developing Kaposi sarcoma

External factors:

  • Previous radiation therapy, especially at a younger age (under 55). Here, the risk of undifferentiated pleomorphic sarcomas and angiosarcomas in the irradiated area is particularly increased.

Although these factors can increase the risk, this does not mean that everyone with these risk factors will inevitably develop a soft tissue tumor. In the vast majority of people affected, no risk factor is found.

Symptoms of soft tissue tumors

Soft tissue tumors are such a diverse group that there are no typical symptoms. If a soft tissue tumor lies near the surface, it can cause visible or palpable, usually painless swellings or hardened areas. If a tumor grows deep in the body and presses on other organs or nerves, this can cause further complaints, such as pain or limited mobility. Unexplained swellings should be checked by a doctor – even if they do not hurt.

When are soft tissue tumors treated?

To treat soft tissue tumors, an accurate diagnosis must first be made. Usually, imaging is done first, with MRI or CT. Then a tissue sample (biopsy) is taken and the tumor is examined and at the molecular level. This makes it possible to determine which type of soft tissue tumor is present. The treatment depends on this. Important: even the tissue sample should be planned at a center specialized in sarcomas, because a poorly placed biopsy can make the later surgery more difficult.

How are soft tissue tumors treated?

The aim of treating soft tissue tumors is to remove the tumor completely and permanently at its site. In addition, metastasis, that is, the formation of secondary tumors elsewhere in the body, should be prevented or treated. The treatment strategy depends, among other things, on which soft tissue tumor is present, where it is located, how aggressive it is, and how far the disease has progressed. Treatment options include:

  • Surgical removal: Complete removal of the tumor with a margin of healthy tissue is the most important treatment. Surrounding structures may also have to be removed.
  • Plastic and reconstructive procedures: If a soft tissue tumor is in an unfavorable location, surgical reconstruction or a tissue transplant may be necessary.
  • Radiation therapy: It is used in addition to surgery for larger or aggressive tumors – before or after the operation – to prevent the tumor from coming back at its original site.
  • Drug therapy: Chemotherapy can be given before (neoadjuvant) or after (adjuvant) surgery, especially when the risk of relapse is high. For metastases, chemotherapies (e.g. doxorubicin) and, depending on the subtype, targeted drugs are available.

How exactly have clinical trials changed the treatment landscape for soft tissue tumors?

Because the disease is rare, it is more difficult to conduct trials. A particular challenge is that the many subtypes differ in how they respond to therapies. Nevertheless, clinical trials have substantially improved the treatment of soft tissue tumors. Here are two examples:

Liposarcomas (LPS), at 10–15 % of all soft tissue sarcomas, are among the most common soft tissue tumors. For this group, there are analyses by the European Organisation for Research and Treatment of Cancer (EORTC). They showed that the subtypes respond differently to chemotherapy: myxoid liposarcoma in particular responds well to such as doxorubicin, while other subtypes respond much less well. So the subtype helps decide whether chemotherapy makes sense.

Leiomyosarcomas (LMS) are another common subgroup. Trials in this disease have, for example, investigated whether chemotherapy with the drug gemcitabine works well. It is used mainly when the disease progresses despite previous treatment. The American SARC-002 trial compared gemcitabine alone with the combination of gemcitabine and docetaxel in 122 patients. It showed that the combination therapy is more effective. A second trial from France, TAXOGEM, however, could not confirm this benefit in leiomyosarcomas – an example of why individual trial results need to be verified.

Interested in taking part in clinical trials? Then take a look here at the current trials in Germany.

This information is not a substitute for a conversation with your doctor.